Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FCRU6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $99,325
Award facts
- Contract value 100% obligated
- $99,325.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $99,325 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of ENTYVIO 300 mg vials. The award, issued on January 12, 2026, with an ultimate completion date of January 13, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded in November 2025 with a $499.999 billion ceiling value and extends through December 31, 2036.
The delivery order supports the Department of Defense's medical supply requirements through the DLA's Medical Supply Chain division. DMS Pharmaceutical Group has been a registered System for Award Management vendor since 2001 and maintains an extensive product portfolio encompassing branded and generic pharmaceuticals, biologics, and medical consumables. The company's established performance on numerous delivery orders under the PPV-G GEN V program—which represents a $30.3 billion acquisition strategy to supply military healthcare facilities worldwide—positions it as a critical pharmaceutical supplier within the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCRU6?
SPE2DR26FCRU6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FCRU6 worth?
The government has obligated $99,325 on SPE2DR26FCRU6.
Is contract SPE2DR26FCRU6 an order under another contract?
Yes. SPE2DR26FCRU6 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRU6 competed?
The extent of competition for SPE2DR26FCRU6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award